Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells
Keystone
Basel-based pharmaceutical company Novartis has received approval for its personalised cell therapy Kymriah in Switzerland. Children and adults who suffer from certain types of blood cancer will be able to undergo the one-time treatment, which is set to cost CHF370,000 ($371,000).
Kymriah is already registered in the US, the EU and other countries. In the US, the treatment costs $475,000; the EU has said it will work with health officials to find fair, value-based pricing.
As in the US, pricing in Switzerland is set to be linked to the success of the therapy, although the details were still being worked out, said Kay Moeller-Heske, head of oncology at Novartis Switzerland, on Monday. The drug is not covered by obligatory health insurance, he added.
Kymriah involves white blood cells of patients being genetically modified so that they recognise and attack cancer cells. Novartis is the first Swiss pharmaceutical company to be approved for such therapy.
The number of possible treatment centres in Switzerland would initially be very limited as the Kymriah cell therapy places high demands on the production facilities and the staff, according to Moeller-Heske.
He pointed out, however, that the number of patients was expected to be very low at first: a “low two-digit number” of patients, with four or five being children.
What is Kymriah and what does it do?
Kymriah, formerly known as CTL019, is a type of immunotherapyExternal link known as a chimeric antigen receptor T cell (CAR-T) therapy, and is first of its kind to receive FDA approval. Kymriah is intended for use in patients with a specific type of childhood leukaemia known as ALLExternal link. It is a one-time treatment that involves modifying a patient’s own T-cells – a type of white blood cell – and then using them to target and destroy cancer cells. Until now, ALL has had a very poor survival rate – fewer than 10% of patients survive five yearsExternal link.
More
More
Will exclusive collaborations yield more drug breakthroughs?
This content was published on
Recently FDA-approved, Novartis’s pioneering immunotherapy was developed through an agreement with University of Pennsylvania researchers.
Switzerland could produce up to 5Mt of emissions annually by 2050
This content was published on
Two to five megatonnes of CO2 equivalents per year: this is the amount of greenhouse gas emissions that Switzerland is still expected to produce annually in 2050, a new study shows.
US tariffs putting 100,000 jobs at risk in Switzerland
This content was published on
US tariffs of 39% on Swiss imports will directly affect 100,000 jobs, mainly in the watchmaking, machinery, metals, and food industries, economiesuisse warns.
This content was published on
Switzerland has released CHF4 million (nearly $5 million) to help Sudan, which has been severely affected by famine and cholera.
Switzerland rejects new Israeli settlements in Palestinian territory
This content was published on
Switzerland says it rejects the announced construction of thousands of housing units in the Israeli-occupied Palestinian West Bank.
Larry Finck and André Hoffmann named interim co-chairs of WEF board
This content was published on
The WEF also revealed an investigation commissioned by the board has cleared its founder Klaus Schwab and his wife of accusations made by anonymous whistleblowers.
Vice-president of German parliament in favour of Switzerland joining EU
This content was published on
The vice-president of the Bundestag says his country should support closer ties between Switzerland and the European Union given the customs conflict with the United States.
Lindt & Sprüngli reportedly considering shifting Easter bunny production to US
This content was published on
Swiss chocolate manufacturer Lindt & Sprüngli could relocate the production of its gold-wrapped Easter bunnies to the US in order to circumvent the import tariffs imposed by the Trump administration.
Swiss petition launched against curbing 30km/h speed limit
This content was published on
The Traffic Club of Switzerland (TCS) has submitted a petition to the Federal Chancellery, challenging the 30km/h speed limit on local roads.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis’s new $475,000 cancer drug among most expensive ever
This content was published on
Bruno Strigini, chief executive of oncology at Novartis, said: “We carefully considered the appropriate price and looked at many factors, including the medical and clinical value.” He was speaking on Wednesday shortly after the treatment was approved by the US Food and Drug Administration (FDA), which gave Novartis a green light to use the medicine…
This content was published on
The increases are primarily due to demographic changes. There are increasing numbers of old people in the population, and old people tend to have more chronic diseases, said Pascale Strupler, director of the Swiss Federal Office of Public Health, at a press conference on Monday. The good news: the risk of dying from cancer decreased…
Study finds increased paediatric cancer risk near motorways
This content was published on
Researchers from the Institute for Social and Preventive Medicine (ISPM) looked for relationships between proximity to a Swiss motorway and the number of cancer cases registered in children between 1985 and 2008. They found that children growing up within 100 metres of a motorway had a 47% to 57% higher risk of contracting leukaemia. Despite…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.